Exact Sciences (EXAS)
(Real Time Quote from BATS)
$58.38 USD
+2.02 (3.58%)
Updated Aug 15, 2024 03:46 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 141 - 160 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Reset Expectations w/ Light 2016 Guide; USPSTF Uncertainties Linger
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Pre-call Summary - Test Volume Looked Above Street - Just Below Wedbush - GMs Better - Offset By Worse Opex - No Guidance - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q15 Recap - Volume Ok - 4Q - 2016 Guidance Soft - GMs Better - Offset By Worse Opex - Lowering PT to $6.50 - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Expecting Slightly Better 3Q15 Volume - Sales - Private Payor Discussions - Cologuard Ramp Key - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Lowering PT from $18 to $7 After Model Rebuild - Slim Chance of USPSTF Opinion Change - Out Year Adoption More Questionable - Little Margin for Error
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
USPSTF "Alternative" Designation Not as Favorable as Anticipated
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
USPSTF Draft Not Exactly a Ringing Endorsement for Cologuard
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
USPSTF Draft Not Exactly a Ringing Endorsement for Cologuard - Perhaps It''s Just Enough - We''d Be Buyers Below Our Price Target of $18
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare - 3Q 2015: Quarterly Medical Technology Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q/3Q Inline with Preannouncement; Stock Offering Announced
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Relatively Uneventful 2Q15 Call - 3Q Guidance Reiterated - GMs - Opex Better
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Medical Technology: 2Q15 Quarterly Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q15 Recap - Solid Improvement Over 4Q Call - 2Q Vol. Guidance Is Enough - Tone Confident - Positive Summer Catalysts On Track - Maintain LT NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Pre-Call Summary: Test Volume In Line with Street View - Below Wedbush Street-High Model - Doc Adds Look Better - No Guidance - Opex Fine - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z